^
    BRAF V600E
    Glioma
    trametinib + dabrafenib
    Sensitive: C1 - Off-label
    Lancet Oncol - 3 days
    IDH2 mutation
    GBM
    AV-GBM-1
    Sensitive: C3 – Early Trials
    SITC 2021 - 2 weeks
    IDH1 mutation
    GBM
    AV-GBM-1
    Sensitive: C3 – Early Trials
    SITC 2021 - 2 weeks
    MGMT promoter methylation
    GBM
    AV-GBM-1
    Sensitive: C3 – Early Trials
    SITC 2021 - 2 weeks
    No biomarker
    GBM
    Byvasda (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Brain Cancer
    lomustine
    Sensitive: A1 - Approval
    No biomarker
    Astrocytoma
    everolimus
    Sensitive: A1 - Approval
    No biomarker
    Astrocytoma
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    Ependymoma
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    Medulloblastoma
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    Anaplastic Astrocytoma
    temozolomide
    Sensitive: A1 - Approval
    No biomarker
    GBM
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Glioma
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    GBM
    temozolomide
    Sensitive: A1 - Approval
    No biomarker
    GBM
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    GBM
    Zirabev (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    GBM
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    GBM
    Krabeva (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Glioma
    teserpaturev
    Sensitive: A1 - Approval
    VHL mutation
    CNS Tumor
    belzutifan
    Sensitive: A1 - Approval
    BRAF V600E
    GBM
    trametinib + dabrafenib
    Sensitive: A2 - Guideline
    No biomarker
    GBM
    PCV
    Sensitive: A2 - Guideline
    No biomarker
    Anaplastic Astrocytoma
    PCV
    Sensitive: A2 - Guideline
    No biomarker
    Glioma
    PCV
    Sensitive: A2 - Guideline
    MGMT promoter methylation
    GBM
    temozolomide
    Sensitive: A2 - Guideline
    No biomarker
    Oligodendroglioma
    temozolomide
    Sensitive: A2 - Guideline
    No biomarker
    Glioma
    temozolomide
    Sensitive: A2 - Guideline
    No biomarker
    Meningioma
    bevacizumab + everolimus
    Sensitive: A2 - Guideline
    No biomarker
    Meningioma
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Meningioma
    sunitinib
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    cisplatin + cyclophosphamide oral + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    cisplatin + vincristine + lomustine
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    trametinib + dabrafenib
    Sensitive: A2 - Guideline
    No biomarker
    Glioma
    bevacizumab
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    vemurafenib + cobimetinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    vemurafenib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    trametinib + dabrafenib
    Sensitive: A2 - Guideline
    No biomarker
    Astrocytoma
    lomustine + procarbazine hydrochloride + vincristine liposomal
    Sensitive: A2 - Guideline
    No biomarker
    GBM
    lomustine
    Sensitive: A2 - Guideline
    No biomarker
    GBM
    regorafenib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    vemurafenib + cobimetinib
    Sensitive: A2 - Guideline
    No biomarker
    Astrocytoma
    temozolomide gel
    Sensitive: A2 - Guideline
    BRAF V600E
    Glioma
    selumetinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    cobimetinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    vemurafenib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    trametinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Astrocytoma
    dabrafenib
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    cobimetinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    trametinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Ganglioglioma
    dabrafenib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Glioma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Glioma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Glioma
    larotrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Glioma
    lomustine
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Glioma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Glioma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Glioma
    entrectinib
    Sensitive: A2 - Guideline
    BRAF V600E
    GBM
    vemurafenib + cobimetinib
    Sensitive: A2 - Guideline
    BRAF fusion
    Glioma
    selumetinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    GBM
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    GBM
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    GBM
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    GBM
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    GBM
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    GBM
    entrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Ependymoma
    lomustine
    Sensitive: A2 - Guideline
    No biomarker
    Ependymoma
    etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Glioma
    etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    cyclophosphamide oral
    Sensitive: A2 - Guideline
    No biomarker
    Ependymoma
    lapatinib
    Sensitive: A2 - Guideline
    No biomarker
    Ependymoma
    temozolomide
    Sensitive: A2 - Guideline
    No biomarker
    Ependymoma
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Meningioma
    DG3173
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    vismodegib
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    cisplatin + etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    temozolomide
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    cyclophosphamide oral + etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Medulloblastoma
    carboplatin + cyclophosphamide oral + etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    GBM
    VAL-083
    Sensitive: B - Late Trials
    No biomarker
    GBM
    enzastaurin
    Sensitive: B - Late Trials
    No biomarker
    GBM
    DNX-2401
    Sensitive: B - Late Trials
    H3.3K27M
    Glioma
    ONC201
    Sensitive: B - Late Trials
    No biomarker
    GBM
    GDC-0084
    Sensitive: B - Late Trials
    MGMT unmethylation
    GBM
    temozolomide
    Sensitive: B - Late Trials
    IDH1 mutation
    Glioma
    temozolomide gel
    Sensitive: B - Late Trials
    IDH1 R132H
    Anaplastic Astrocytoma
    temozolomide
    Sensitive: B - Late Trials
    IDH2 mutation
    Glioma
    temozolomide
    Sensitive: B - Late Trials
    IDH1 mutation
    Glioma
    temozolomide
    Sensitive: B - Late Trials
    MGMT promoter methylation
    Anaplastic Astrocytoma
    temozolomide
    Sensitive: B - Late Trials
    IDH2 mutation
    Glioma
    temozolomide gel
    Sensitive: B - Late Trials
    IDH1 mutation
    Glioma
    PCV
    Sensitive: B - Late Trials
    IDH2 mutation
    Glioma
    PCV
    Sensitive: B - Late Trials
    No biomarker
    GBM
    GLR2007
    Sensitive: B - Late Trials
    No biomarker
    GBM
    VB-111
    Sensitive: B - Late Trials
    No biomarker
    Glioma
    OKN-007
    Sensitive: B - Late Trials